GLP-1 receptor agonists

About Us

Bharti Rana Jayshankar – Founder

She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.

Jay Shankar – Co-founder

He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.

Contact Info

info@healthquill.com

GLP-1 based weight-loss drugs have some therapeutic benefits, but the risks are as high

New insights on GLP-1 drugs: Benefits and risks unveiled

HQ Team January 21, 2024: The popular diabetes drugs, glucagon-like peptide-1 (GLP-1) receptor agonists such as Ozempic, have gained immense popularity for their.

by HealthQuill
January 21, 2025
0 Comments

About Us

Contact Info

Follow Us

New insights on GLP-1 drugs: Benefits and risks unveiled